Stock information

VALBIOTIS is a Research & Development company committed to scientific innovation for preventing and combating metabolic diseases in response to unmet medical needs.

VALBIOTIS has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of nutritional health solutions designed to reduce the risk of major metabolic diseases, based on a multi-target approach and made possible by the use of plant-based ingredients.

Its products are intended to be licensed to players in the health sector. VALBIOTIS has been listed on Euronext Growth since 7 June 2017.

• Label: Valbiotis
• Mnemonic: ALVAL
• ISIN Code: FR 0013254851
• PEA PME eligible: Oui
• Trading Market:
  • ALTERNEXT ALLSHARE
  • NEXT BIOTECH
• Total number of shares: 7,671,144